Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients (CRAGMOLC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03489616 |
Recruitment Status : Unknown
Verified March 2018 by Jinming Yu, Shandong Cancer Hospital and Institute.
Recruitment status was: Recruiting
First Posted : April 5, 2018
Last Update Posted : April 5, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Carcinoma, Non-Small-Cell Lung | Biological: rhGM-CSF Drug: Pemetrexed Radiation: Local Radiotherapy Drug: Single agent | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 45 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients Without Progression After First-line Chemotherapy: a Prospective Randomized Controlled Study |
Actual Study Start Date : | January 15, 2018 |
Estimated Primary Completion Date : | July 1, 2019 |
Estimated Study Completion Date : | December 31, 2019 |
Arm | Intervention/treatment |
---|---|
Experimental: Radiotherapy+chemotherapy+ rhGM-CSF
Patients with PR or SD after first-line chemotherapy will be treated with pemetrexed on d1 (500mg/m2) or other single agent on d1, d8. Local radiotherapy dose will be> 4Gy per time(or BED >45Gy) from day 2 to day 15 in a cycle of 21 days. Subcutaneous injection of rhGM-CSF (200ug/m² per day) will be executed 24 hours after chemotherapy. Repeat in the second metastatic lesions.
|
Biological: rhGM-CSF
rhGM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils. rhGM-CSF can promote the maturation of dendritic cells and macrophage, increase their antigen presentation ability.
Other Name: Recombinant human granulocyte macrophage stimulating factor Drug: Pemetrexed Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer. Radiation: Local Radiotherapy Radiotherapy promotes the release of tumor antigen
Other Name: Local Radiation therapy Drug: Single agent Other chemotherapy drugs,such as Docetaxel, gemcitabine
Other Name: Single agent for maintenance therapy |
Experimental: Single agent maintenance therapy
Maintenance treatment by single agent in a cycle of 21 days.
|
Drug: Single agent
Other chemotherapy drugs,such as Docetaxel, gemcitabine
Other Name: Single agent for maintenance therapy |
- PFS [ Time Frame: 2 years ]Progression-Free-Survival
- Abscopal effect rate [ Time Frame: At the time point of 4 weeks after completion of rhGM-CSF ]Radiotherapy-induced immune-mediated tumour regression at sites distant to the irradiated field
- OS [ Time Frame: 2 years ]Overall survival

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Stage IV NSCLC patients without clear driving genes who were PR or SD after standard first-line chemotherapy;
- Patients who were oligometastasis evaluated by PET-CT or other examinations after first-line chemotherapy. Eligible patients should have 2 to 5 distant metastases (at least 2 metastases were suitable for low fractionated radiotherapy). At least one distant measurable lesion outside the radiation sites.
- Age varied from 18 to 75 years old.
- ECOG performance status 0-2.
- Expected lifespan ≥3 months.
- Absolute neutrophil count (ANC) ≥1.5×109/L, Platelets ≥100×109/L, Hemoglobin ≥90 g/L.
- Able to understand and give written informed consent and comply with study procedures.
Exclusion criteria
- Allergy of rhGM-CSF and its accessories.
- Disease of systemic immune or immune disorders.
- Histology confirmed small cell carcinoma or other malignant compositions in the cancer tissue.
- Patients with thrombotic disease or platelets ≥600×109/L
- Cancer history within 5 years apart from NSCLC before enrollment.
- Tumor related immunotherapy within 4 weeks, including but not limited to immune cell therapy, tumor vaccine therapy, Immune checkpoint therapy, and other immunomodulators (such as thymosin, lentinan) except for rhGM-CSF.
- The abnormality of kidney , heart or lung functions(serum creatinine, Cr>177mol/L; serum AST or ALT more than 2 times above normal limits; total bilirubin, TBIL>34mol/L).
- HIV virus, hepatitis C virus or T lymphocyte virus (type1 or type 2) infection and active hepatitis or other uncontrolled infections.
- Women in pregnancy or lactation.
- Others who do not meet the inclusion criteria.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03489616
Contact: Ming Huan Li, doctor | 131 5303 5389 | sy_lmh2001@163.com | |
Contact: JINMING YU, doctor | 13806406293 ext 0531-87984729 | jn7984729@public.jn.sd.cn |
China, Shandong | |
Shandong Cancer Hospital and Institute | Recruiting |
Jinan, Shandong, China, 250000 | |
Contact: MINGHUAN LI, Doctor 13153035389 ext 0531-67626112 Sy_lmh2001@163.com | |
Contact: JIMING YU, Doctor 13806406293 ext 0531-87984729 jn7984729@public.jn.sd.cn | |
SHANDONG Cancer Hospital | Recruiting |
Jinan, Shandong, China, 250000 |
Principal Investigator: | JINMING YU, doctor | Shandong Cancer Hospital and Institute |
Responsible Party: | Jinming Yu, chief physician, Shandong Cancer Hospital and Institute |
ClinicalTrials.gov Identifier: | NCT03489616 |
Other Study ID Numbers: |
SDCH201701LC |
First Posted: | April 5, 2018 Key Record Dates |
Last Update Posted: | April 5, 2018 |
Last Verified: | March 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Carcinoma, Non-Small-Cell Lung Carcinoma, Bronchogenic Bronchial Neoplasms Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms |
Lung Diseases Respiratory Tract Diseases Pemetrexed Antineoplastic Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Folic Acid Antagonists Nucleic Acid Synthesis Inhibitors |